139 related articles for article (PubMed ID: 26637902)
1. Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.
Aso T; Uozaki H; Morita S; Kumagai A; Watanabe M
Anticancer Res; 2015 Dec; 35(12):6819-27. PubMed ID: 26637902
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
3. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of ARID1A in gastric cancer and paired adjacent noncancerous tissues].
Zhang X; Wang S; Liu N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jan; 33(1):77-80. PubMed ID: 28031120
[TBL] [Abstract][Full Text] [Related]
7. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
8. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.
Cajuso T; Hänninen UA; Kondelin J; Gylfe AE; Tanskanen T; Katainen R; Pitkänen E; Ristolainen H; Kaasinen E; Taipale M; Taipale J; Böhm J; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P
Int J Cancer; 2014 Aug; 135(3):611-23. PubMed ID: 24382590
[TBL] [Abstract][Full Text] [Related]
10. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
11. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
12. DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells.
Jiang ZH; Dong XW; Shen YC; Qian HL; Yan M; Yu ZH; He HB; Lu CD; Qiu F
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(17):3194-200. PubMed ID: 26400522
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer.
Zhu YP; Sheng LL; Wu J; Yang M; Cheng XF; Wu NN; Ye XB; Cai J; Wang L; Shen Q; Wu JQ
Hum Pathol; 2018 Aug; 78():28-35. PubMed ID: 29689245
[TBL] [Abstract][Full Text] [Related]
14. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
15. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
16. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.
Abe H; Hayashi A; Kunita A; Sakamoto Y; Hasegawa K; Shibahara J; Kokudo N; Fukayama M
Int J Clin Exp Pathol; 2015; 8(3):2763-70. PubMed ID: 26045782
[TBL] [Abstract][Full Text] [Related]
18. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies.
Lee SY; Kim DW; Lee HS; Ihn MH; Oh HK; Park DJ; Kim HH; Kang SB
Oncology; 2015; 88(4):234-40. PubMed ID: 25503393
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma.
Kim MJ; Gu MJ; Chang HK; Yu E
Histopathology; 2015 Mar; 66(4):508-16. PubMed ID: 25400081
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
